Fate Therapeutics (FATE) Profit After Tax (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Profit After Tax data on file, last reported at -$31.2 million in Q1 2026.

• Quarterly Profit After Tax rose 17.2% year-over-year to -$31.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$129.9 million (up 26.04% YoY) and the FY2025 annual result came in at -$136.5 million, up 26.63% from the prior year.
• Profit After Tax rose to -$31.2 million in Q1 2026, from -$32.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$18.9 million in Q1 2023 to a low of -$83.6 million in Q3 2022.
• A 5-year average of -$46.8 million and a median of -$45.2 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax jumped 71.26% — and 2024, when it tumbled 154.25%.
• Tracing FATE's Profit After Tax over 5 years: stood at -$55.0 million in 2022, then climbed by 19.73% to -$44.1 million in 2023, then declined by 17.63% to -$51.9 million in 2024, then surged by 37.55% to -$32.4 million in 2025, then increased by 3.7% to -$31.2 million in 2026.
• The last three Profit After Tax figures came in at -$31.2 million (Q1 2026), -$32.4 million (Q4 2025), and -$32.2 million (Q3 2025), per Business Quant data.